A PHASE IIb, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Genentech, Inc.0 个研究点目标入组 930 人开始时间: 2021年11月1日最近更新: 2024年4月22日

研究概览

暂无简介。

•Age 40-90 years
•Documented physician diagnosis of COPD for at least 12 months
•History of frequent exacerbations, defined as having had two or more moderate or severe exacerbations occurring within a 12-month period in the 24 months prior to screening
•Post-bronchodilator FEV1 >=20 and <80% of predicted normal value at screening
•Modified Medical Research Council (dyspnea scale) (mMRC) score >=2
•Current or former smoker with a minimum of 10 pack-year history
•History of one of the following combinations of optimized, stable, standard-of-care COPD maintenance therapy for at least 4 weeks prior to screening, with no anticipated changes in therapy prior to initiation of study drug and throughout the study:
•-Inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA)
•-Long-acting muscarinic antagonist (LAMA) plus LABA
•-ICS plus LAMA plus LABA
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 465
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 465

•Current documented diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines within 5 years prior to screening
•History of clinically significant pulmonary disease other than COPD
•History of long-term treatment with oxygen at >4.0 liters/minute
•Lung volume reduction surgery or procedure within 12 months prior to screening
•Participation in or planned participation in a new pulmonary rehabilitation program. Patients who are in the maintenance phase of a rehabilitation program are eligible
•History of lung transplant
•Occurrence of moderate or severe COPD exacerbation, COVID-19, upper or lower respiratory infection, pneumonia, or hospitalization of 24 hours duration within 4 weeks prior to initiation of study drug
•Treatment with oral, IV, or IM corticosteroids within 4 weeks prior to initiation of study drug
•Initiation of a methylxanthine preparation, maintenance macrolide therapy, and/or PDE4 inhibitor within 4 weeks prior to screening
•Unstable cardiac disease, myocardial infarction, or New York Heart Association Class III or IV heart failure within 12 months prior to screening

发起方